| Patient | Ronald Reagan |
|---|---|
| Date of birth | 1911-02-06 |
| Identifiers | MRN HR-ML008-SYN-TD; SSN (made up) 000-08-6047 |
| Document date | 2001-04-14 |
| Author | Margaret Ellison, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month post-fracture review with bone density testing and zoledronic acid. [S]
Mr. Reagan returns three months after the repair of his right hip fracture. He now walks in the house and out to the garden with his walker and supervision, and enjoys sitting outside. His hip no longer hurts, even after walking, and he has had no falls. Home physical therapy continues twice a week. His caregivers give cholecalciferol every day and report no missed doses of it or of donepezil. The evening restlessness is mild and unchanged, and the evening routine still settles it. His appetite is good, and he has gained 1 kg. [S]
| Element | Detail |
|---|---|
| Interval change | Walking in the house and garden with a walker and supervision; no hip pain |
| Falls | None |
| Medicines | Donepezil and cholecalciferol taken daily; acetaminophen no longer needed |
| Behavior | Mild evening restlessness, unchanged |
| Function | Barthel Index 75, up from 55 at the first visit |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Appetite good; weight up 1 kg; no fever |
| Cardiovascular | Negative | No lightheadedness on standing or fainting |
| Gastrointestinal | Negative | No heartburn, nausea, or trouble swallowing |
| Musculoskeletal | Negative | No hip pain; no back pain |
| Neurological | Positive | Known memory loss, unchanged |
| Psychiatric | Positive | Mild evening restlessness; no low mood; GDS-15 score 3 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Donepezil 10 mg oral tablet, one tablet by mouth daily in the morning | One tablet by mouth daily in the morning | Oral route | 1997-03-07 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets (1,000 mg) by mouth three times daily | Two tablets by mouth three times daily | Oral route | 2001-01-14 to 2001-04-14 | completed | S |
| Oxycodone 5 mg oral tablet, one tablet by mouth every six hours as needed for severe pain | One tablet by mouth every six hours as needed for severe pain | Oral route | 2001-01-14 to 2001-02-10 | stopped | S |
| Diphenhydramine 25 mg oral capsule, one capsule by mouth at bedtime | One capsule by mouth at bedtime | Oral route | 2001-01-16 to 2001-02-10 | stopped | S |
| Enoxaparin 40 mg/0.4 mL prefilled syringe, inject 40 mg under the skin daily through day 35 after surgery | Inject 40 mg under the skin once daily | Subcutaneous route | 2001-01-14 to 2001-02-17 | completed | S |
| Cholecalciferol 50 mcg (2,000 units) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2001-02-10 | active | S |
| Zoledronic acid 5 mg/100 mL intravenous infusion over at least 15 minutes, once yearly | 5 mg intravenously over at least 15 minutes once a year; first dose given | Intravenous route | 2001-04-14 to 2001-04-14 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2001-04-14 | Body height | 185 | cm | S |
| 2001-04-14 | Body weight | 77.5 | kg | S |
| 2001-04-14 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2001-04-14 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2001-04-14 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2001-04-14 | Heart rate | 64 | /min | S |
| 2001-04-14 | Respiratory rate | 16 | /min | S |
| 2001-04-14 | Body temperature | 36.6 | Cel | S |
| 2001-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2001-04-14 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2001-04-14 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2001-04-14 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2001-04-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2001-04-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1996)/1.73 sq M | 63 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2001-04-14 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2001-04-14 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2001-04-14 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 36 | ng/mL | 30-100 ng/mL | Normal | S |
| 2001-04-14 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 112 | U/L | 40-129 U/L | Normal | S |
| 2001-04-14 | DXA Hip - left [Mass/Area] Bone density | 0.637 | g/cm2 | >=0.896 g/cm2 | Low | S |
| 2001-04-14 | Total score Barthel Index | 75 | {score} | S | ||
| 2001-04-14 | Geriatric depression scale (GDS) short version total | 3 | {score} | S |
Vital signs recorded on 2001-04-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert, pleasant, and well groomed |
| Cardiovascular | Regular rhythm at 64 per minute; no edema; no fall in blood pressure on standing, without symptoms |
| Musculoskeletal | Right hip incision well healed; painless hip movement; no spinal tenderness; walks with the walker and supervision, steadier than at the last visit |
| Neurological | Oriented to person, not to date; no focal weakness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Alzheimer's disease with late onset, disclosed in 1969 | active | confirmed | G30.1 | S — Synthetic modern coding of the publicly disclosed diagnosis. |
| Dementia due to Alzheimer's disease, moderate (FAST stage 5), with evening restlessness | active | confirmed | F02.B0 | S — Synthetic stage; his actual stage at this age was not made public. |
| Osteoporosis with right hip fragility fracture after a fall at home, repaired with internal fixation; subsequent care | active | confirmed | M80.051D | S — Synthetic modern coding of the documented January 2001 hip fracture as an osteoporotic fracture; bone density and fracture pattern are synthetic. |
| Vitamin D deficiency | resolved | confirmed | E55.9 | S — Synthetic finding from the first-visit 25-hydroxyvitamin D; repleted by three months. |
| Acute blood loss anemia after hip surgery | resolved | confirmed | D62 | S — Synthetic postoperative finding; resolved by three months. |
| History of falling | active | confirmed | Z91.81 | S — Synthetic modern coding linked to the documented fall. |
| Personal history of colon cancer, operated on in 1960 | active | confirmed | Z85.038 | S — Synthetic modern coding of the documented 1985 operation. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Serum calcium and kidney function before zoledronic acid | Before each intravenous dose | Completed today | Calcium 9.3 mg/dL; creatinine 1.08 mg/dL, eGFR 63, creatinine clearance about 50 mL/min, above the 35 mL/min limit |
| Laboratory | 25-hydroxyvitamin D and alkaline phosphatase after repletion | Repeat after repletion, then yearly | Completed today | Vitamin D 36 ng/mL, up from 16; alkaline phosphatase back to normal at 112 U/L |
| Laboratory | Hemoglobin | Follow-up of postoperative anemia | Completed today | 13.4 g/dL, up from 11.1 |
| Laboratory | Phosphorus and 24-hour urine calcium | Once, in the secondary-causes workup before treatment | Deferred | Not obtained before today's infusion, a deviation from the protocol. Serum calcium, PTH, and alkaline phosphatase point to vitamin D deficiency as the only secondary cause, so a missed cause that would change treatment is unlikely. Phosphorus will be added to the tests before the second infusion; a 24-hour urine collection only if bone density falls on treatment |
| Laboratory | Bone turnover markers (CTX or P1NP) | Baseline and 3 to 6 months after starting therapy | Not indicated | An infusion given in clinic makes adherence certain, and BHOF treats the markers as optional |
| Imaging | DXA of the hip and spine | Baseline after the fracture; every 1 to 3 years on therapy | Completed today | Left total hip T-score -2.8 (0.637 g/cm²); lumbar spine T-score -1.9 |
| Imaging | Vertebral fracture assessment | At baseline after a low-trauma fracture or with a T-score of -2.5 or lower | Deferred | Not done with today's DXA although both triggers apply, a deviation from the protocol. Treatment is already indicated by the hip fracture, so the decision is unchanged; he has no back pain and no height loss. Add it to the next DXA, sooner if back pain or height loss appears |
| Survey | FRAX 10-year fracture risk | After the fracture and with each DXA | Deferred | Not calculated with today's DXA, a deviation from the protocol. The hip fracture already establishes the need for treatment, so the decision is unaffected; calculate it with the next DXA |
| Medication safety | Antiresorptive therapy after the fracture | Promptly, within months of the fracture | Completed today | Zoledronic acid 5 mg given today, three months after the repair, once vitamin D was repleted |
| Examination | Standing height | Yearly | Completed today | 185 cm, unchanged |
| Examination | Pain assessment | Every visit | Completed today | No hip pain; scheduled acetaminophen stopped |
| Examination | Physical and occupational therapy progress | Every visit | Completed today | Barthel Index 75, up from 55; walking goal met |
| Examination | CDC STEADI fall-risk screen: fall history, gait and balance, postural blood pressure | Every primary care visit after the fracture | Completed today | No falls; steadier with the walker; no fall in blood pressure on standing |
| Examination | Timed Up and Go | When home therapy ends, then yearly or with a change | Due | Planned when home therapy ends, by the six-month review |
| Examination | Hip radiographs | Only for pain, loss of function, or suspected nonunion | Not indicated | No pain and steady progress |
| Examination | Home safety evaluation | At diagnosis and each follow-up | Completed today | Changes from the home safety assessment still in place |
| Medication safety | AGS Beers Criteria medication review | Every visit and at each transition of care | Completed today | Acetaminophen stopped; no Beers-listed medicine |
| Medication safety | Cholinesterase inhibitor benefit and tolerability | Each follow-up | Completed today | Heart rate 64; no fainting; continue |
| Survey | Neuropsychiatric symptom screen (NPI-Q) | Every visit | Completed today | Mild evening restlessness, unchanged; no hallucinations or aggression |
| Survey | Depression screen (GDS-15) | At 1, 3, and 6 months after the fracture; yearly in dementia | Completed today | Score 3, below the threshold of 5 |
| Survey | Cognitive test (MoCA), FAST stage, and ADL and IADL scores | At diagnosis, then yearly | Up to date | Done at the first visit and confirmed by neurology; next in about ten months |
| Survey | Caregiver assessment with the Zarit Burden Interview | At diagnosis, then every 6 to 12 months | Up to date | Repeat at the six-month review |
| Self-management | Advance care planning | At diagnosis, yearly, and at stage changes | Completed today | POLST form completed |
| Self-management | Calcium intake from food and supplements | Ongoing; target 1,000 to 1,200 mg a day | Completed today | Calcium-rich food at each meal; no calcium tablet needed |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: Management of Hip Fractures in Older Adults Evidence-Based Clinical Practice Guideline (2021); The clinician's guide to prevention and treatment of osteoporosis (2022); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD) (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, hip/pelvic fracture, and osteoporosis monographs (2026)
Follow-up: Six-month post-fracture, dementia, and caregiver review in three months, with calcium and hemoglobin. Next scheduled visit 2001-07-14: six-month post-fracture, dementia, and caregiver review. [S]